 Brandon Mcmahon
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 9 | 2022 | 29 | 1.420 |
Why?
| | Thrombosis | 6 | 2019 | 368 | 1.400 |
Why?
| | Primary Myelofibrosis | 3 | 2025 | 10 | 1.180 |
Why?
| | Urokinase-Type Plasminogen Activator | 4 | 2015 | 29 | 1.030 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2015 | 86 | 0.920 |
Why?
| | Thrombocytopenia | 3 | 2016 | 199 | 0.890 |
Why?
| | Neoplasms | 9 | 2021 | 2666 | 0.870 |
Why?
| | Pyrazoles | 3 | 2025 | 427 | 0.840 |
Why?
| | Anticoagulants | 5 | 2021 | 665 | 0.840 |
Why?
| | Hemorrhage | 5 | 2018 | 723 | 0.810 |
Why?
| | Plasminogen | 3 | 2013 | 30 | 0.730 |
Why?
| | Fibrinolysin | 2 | 2013 | 19 | 0.710 |
Why?
| | Blood Platelets | 3 | 2025 | 405 | 0.650 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 2 | 2015 | 15 | 0.540 |
Why?
| | Liver Cirrhosis | 2 | 2020 | 316 | 0.520 |
Why?
| | Anemia, Pernicious | 1 | 2016 | 9 | 0.510 |
Why?
| | Pancytopenia | 1 | 2016 | 8 | 0.510 |
Why?
| | Hypothyroidism | 1 | 2016 | 71 | 0.490 |
Why?
| | Neoplasm Proteins | 2 | 2009 | 433 | 0.480 |
Why?
| | Myelodysplastic Syndromes | 2 | 2016 | 135 | 0.470 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 49 | 0.440 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 1 | 2013 | 15 | 0.410 |
Why?
| | Heparin | 1 | 2014 | 259 | 0.400 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 849 | 0.380 |
Why?
| | Thrombophilia | 2 | 2009 | 85 | 0.370 |
Why?
| | Medical Oncology | 5 | 2022 | 290 | 0.360 |
Why?
| | Polycythemia Vera | 4 | 2022 | 12 | 0.350 |
Why?
| | Fibrinolysis | 2 | 2009 | 143 | 0.340 |
Why?
| | Nitriles | 2 | 2025 | 175 | 0.310 |
Why?
| | Interferon Type I | 3 | 2015 | 142 | 0.300 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1279 | 0.300 |
Why?
| | Tissue Plasminogen Activator | 2 | 2009 | 225 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1242 | 0.270 |
Why?
| | Antineoplastic Agents | 5 | 2018 | 2145 | 0.270 |
Why?
| | Pyrimidines | 2 | 2025 | 472 | 0.260 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2015 | 455 | 0.260 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 313 | 0.250 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 20 | 0.240 |
Why?
| | Humans | 38 | 2025 | 137514 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.210 |
Why?
| | Thrombocythemia, Essential | 1 | 2022 | 7 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 658 | 0.200 |
Why?
| | Autophagy | 1 | 2025 | 282 | 0.200 |
Why?
| | Interferon-alpha | 2 | 2014 | 198 | 0.200 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 322 | 0.190 |
Why?
| | Telomerase | 2 | 2020 | 250 | 0.180 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 249 | 0.180 |
Why?
| | Venous Thrombosis | 1 | 2021 | 187 | 0.160 |
Why?
| | Mastocytosis, Systemic | 1 | 2018 | 8 | 0.150 |
Why?
| | Mutation | 4 | 2020 | 3964 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2025 | 10821 | 0.150 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 53 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2023 | 521 | 0.150 |
Why?
| | Chicago | 2 | 2016 | 61 | 0.140 |
Why?
| | Eosinophilia | 1 | 2020 | 218 | 0.140 |
Why?
| | Risk Factors | 5 | 2021 | 10356 | 0.140 |
Why?
| | Gene Rearrangement | 1 | 2018 | 151 | 0.140 |
Why?
| | Mitochondria | 2 | 2025 | 947 | 0.140 |
Why?
| | Anaphylaxis | 1 | 2018 | 105 | 0.140 |
Why?
| | Neovascularization, Pathologic | 2 | 2009 | 301 | 0.130 |
Why?
| | Janus Kinase 2 | 2 | 2015 | 32 | 0.130 |
Why?
| | Aging | 2 | 2019 | 1866 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7593 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2009 | 659 | 0.130 |
Why?
| | Philadelphia Chromosome | 1 | 2016 | 18 | 0.130 |
Why?
| | Biomarkers | 3 | 2018 | 4172 | 0.120 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2016 | 79 | 0.120 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2016 | 59 | 0.120 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 69 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2016 | 126 | 0.120 |
Why?
| | Thienamycins | 1 | 2015 | 5 | 0.120 |
Why?
| | Inactivation, Metabolic | 1 | 2015 | 11 | 0.120 |
Why?
| | Piperacillin | 1 | 2015 | 9 | 0.120 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 20 | 0.120 |
Why?
| | Vitamin K | 1 | 2015 | 44 | 0.120 |
Why?
| | Age Factors | 4 | 2015 | 3301 | 0.110 |
Why?
| | False Positive Reactions | 1 | 2014 | 117 | 0.110 |
Why?
| | Aged | 5 | 2025 | 23798 | 0.110 |
Why?
| | Cell Movement | 2 | 2009 | 972 | 0.110 |
Why?
| | Hemostasis | 1 | 2014 | 82 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.110 |
Why?
| | Signal Transduction | 4 | 2016 | 5096 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 89 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 629 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2015 | 221 | 0.100 |
Why?
| | Blood Transfusion | 1 | 2016 | 324 | 0.100 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 533 | 0.100 |
Why?
| | Thrombocytosis | 1 | 2012 | 6 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2016 | 498 | 0.100 |
Why?
| | Adult | 10 | 2022 | 37821 | 0.100 |
Why?
| | Leukocytosis | 1 | 2012 | 31 | 0.100 |
Why?
| | Interferon-beta | 1 | 2013 | 92 | 0.100 |
Why?
| | Pseudomonas Infections | 1 | 2015 | 224 | 0.100 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2012 | 34 | 0.100 |
Why?
| | Middle Aged | 6 | 2025 | 33355 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 872 | 0.100 |
Why?
| | Female | 10 | 2025 | 73162 | 0.100 |
Why?
| | Administration, Oral | 1 | 2015 | 814 | 0.100 |
Why?
| | Annexin A2 | 2 | 2009 | 11 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 414 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2039 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 892 | 0.090 |
Why?
| | Prognosis | 3 | 2016 | 4031 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1402 | 0.090 |
Why?
| | Animals | 9 | 2025 | 37011 | 0.090 |
Why?
| | Male | 9 | 2025 | 67718 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 395 | 0.080 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 424 | 0.080 |
Why?
| | Mice | 7 | 2025 | 17843 | 0.080 |
Why?
| | Phosphoproteins | 1 | 2012 | 338 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 620 | 0.080 |
Why?
| | Apoptosis | 2 | 2009 | 2557 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2014 | 770 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 710 | 0.080 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2009 | 14 | 0.080 |
Why?
| | Cryoglobulins | 1 | 2009 | 6 | 0.080 |
Why?
| | Carboxypeptidase B2 | 1 | 2009 | 3 | 0.080 |
Why?
| | Plasminogen Inactivators | 1 | 2009 | 3 | 0.080 |
Why?
| | Receptors, Peptide | 1 | 2009 | 17 | 0.080 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2009 | 16 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.080 |
Why?
| | Cerebral Infarction | 1 | 2009 | 43 | 0.080 |
Why?
| | Factor VII | 1 | 2008 | 24 | 0.080 |
Why?
| | Edetic Acid | 1 | 2008 | 50 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2755 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2012 | 599 | 0.070 |
Why?
| | von Willebrand Factor | 1 | 2008 | 81 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 127 | 0.070 |
Why?
| | Factor VIII | 1 | 2008 | 99 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2837 | 0.070 |
Why?
| | Time Factors | 2 | 2018 | 6817 | 0.070 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 215 | 0.070 |
Why?
| | Immunoglobulin M | 1 | 2009 | 288 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1458 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 510 | 0.070 |
Why?
| | Bone Marrow | 2 | 2018 | 286 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1312 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2009 | 379 | 0.070 |
Why?
| | Cell Division | 1 | 2009 | 795 | 0.070 |
Why?
| | Blood Coagulation Disorders | 1 | 2009 | 173 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2012 | 1167 | 0.060 |
Why?
| | Ischemia | 1 | 2009 | 408 | 0.060 |
Why?
| | Intestines | 1 | 2009 | 359 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 614 | 0.060 |
Why?
| | Cytokines | 2 | 2014 | 2095 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2015 | 1105 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 1132 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2016 | 15628 | 0.060 |
Why?
| | Janus Kinases | 2 | 2016 | 14 | 0.060 |
Why?
| | Erythroid Cells | 2 | 2015 | 10 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1800 | 0.060 |
Why?
| | Societies, Medical | 2 | 2018 | 820 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 414 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 891 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2003 | 40 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2025 | 3020 | 0.050 |
Why?
| | Virus Integration | 1 | 2003 | 71 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 283 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2003 | 126 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1428 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1320 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 920 | 0.040 |
Why?
| | Autoantibodies | 1 | 2009 | 1501 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1241 | 0.040 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2003 | 255 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 2 | 2014 | 398 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2019 | 33 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1762 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 21 | 0.040 |
Why?
| | mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 29 | 0.040 |
Why?
| | Platelet Activation | 1 | 2019 | 93 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 807 | 0.040 |
Why?
| | Glomerulonephritis, IGA | 1 | 2018 | 11 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2018 | 67 | 0.040 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 44 | 0.040 |
Why?
| | Fibroblasts | 2 | 2014 | 990 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 416 | 0.030 |
Why?
| | Mast Cells | 1 | 2018 | 146 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 321 | 0.030 |
Why?
| | Prevalence | 2 | 2015 | 2719 | 0.030 |
Why?
| | Receptors, Thrombopoietin | 1 | 2016 | 6 | 0.030 |
Why?
| | Thrombopoietin | 1 | 2016 | 5 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2003 | 786 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3420 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2015 | 4206 | 0.030 |
Why?
| | Benzoates | 1 | 2016 | 43 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 784 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 35 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2016 | 94 | 0.030 |
Why?
| | Receptors, Fc | 1 | 2016 | 53 | 0.030 |
Why?
| | General Practice | 1 | 2016 | 30 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 86 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1060 | 0.030 |
Why?
| | Autophagy-Related Protein-1 Homolog | 1 | 2015 | 7 | 0.030 |
Why?
| | Azacitidine | 1 | 2016 | 141 | 0.030 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.030 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 37 | 0.030 |
Why?
| | Response Elements | 1 | 2015 | 91 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 538 | 0.030 |
Why?
| | Nuclear Cap-Binding Protein Complex | 1 | 2014 | 1 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 471 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 691 | 0.030 |
Why?
| | Ubiquitins | 1 | 2014 | 36 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 14 | 0.030 |
Why?
| | Guanosine | 1 | 2014 | 41 | 0.030 |
Why?
| | Interferons | 1 | 2016 | 199 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2014 | 28 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2066 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 567 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 121 | 0.030 |
Why?
| | Risk | 1 | 2016 | 905 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2016 | 665 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 338 | 0.030 |
Why?
| | Eukaryotic Initiation Factor-4E | 1 | 2013 | 27 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 362 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2013 | 145 | 0.030 |
Why?
| | U937 Cells | 1 | 2012 | 25 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 329 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1465 | 0.020 |
Why?
| | Aspirin | 1 | 2015 | 385 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1524 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 232 | 0.020 |
Why?
| | Hospitalists | 1 | 2016 | 245 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2013 | 132 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 660 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2064 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6745 | 0.020 |
Why?
| | Leukemia | 1 | 2013 | 238 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2013 | 244 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 429 | 0.020 |
Why?
| | Splanchnic Circulation | 1 | 2009 | 10 | 0.020 |
Why?
| | Infarction | 1 | 2009 | 10 | 0.020 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 189 | 0.020 |
Why?
| | Blood Specimen Collection | 1 | 2008 | 38 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 88 | 0.020 |
Why?
| | Giant Cell Arteritis | 1 | 2009 | 49 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5792 | 0.020 |
Why?
| | Tretinoin | 1 | 2009 | 123 | 0.020 |
Why?
| | Immunoassay | 1 | 2008 | 114 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 305 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 178 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3439 | 0.020 |
Why?
| | Plasma | 1 | 2008 | 213 | 0.020 |
Why?
| | Spleen | 1 | 2009 | 516 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1695 | 0.020 |
Why?
| | Hospitalization | 1 | 2016 | 2197 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1131 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1979 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5427 | 0.010 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2003 | 285 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2003 | 957 | 0.010 |
Why?
| | United States | 1 | 2018 | 14696 | 0.010 |
Why?
| | Kidney | 1 | 2009 | 1472 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1940 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2180 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2901 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 21555 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1507 | 0.010 |
Why?
|
|
Mcmahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|